Cost‐Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First‐Line Treatment of HER2‐Positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
In China, for first-line treatment of HER2-positive advanced gastric or GEJ adenocarcinoma, the PEM + TRAS + Chemo regimen is not cost-effective when compared to the TRAS + Chemo regimen, unless the price of pembrolizumab is reduced.
Authors
- Hongfei Hu
- Xin‐Yuan Guan (ORCID: https://orcid.org/0000-0002-4485-6017)
- Yongli Zhang (ORCID: https://orcid.org/0000-0001-9574-515X)
- Aixia Ma (ORCID: https://orcid.org/0000-0002-7963-6962)
- Yan Li (ORCID: https://orcid.org/0000-0001-9538-5609)
- Yifang Liang (ORCID: https://orcid.org/0009-0008-2634-2910)
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/cam4.71379
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00